NasdaqGS:INCYBiotechs
Incyte (INCY) In Focus On Trial Results And Vega Deal As Valuation Questions Persist
Why Incyte Stock Is Back in Focus
Incyte (INCY) is back on investor watchlists after publishing full safety and efficacy results from its Phase 1/2 trial of latarcibart for von Willebrand disease and acquiring the drug’s developer, Vega Therapeutics.
See our latest analysis for Incyte.
Incyte’s recent clinical update and Vega Therapeutics acquisition come on the back of solid momentum, with a 90 day share price return of 21.62% and a 1 year total shareholder return of 69.43%. This indicates...